Fig. 2From: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumorsSerum IL-8 levels pre- and post-treatment with HuMax-IL8. The human IL-8 ELISA kit was used to measure free serum IL-8 levels. Reductions in serum IL-8 levels were observed at all dose levels and were significantly reduced on day 3 compared to pre-treatment (p = 0.0004)Back to article page